Emerging Treatments & Clinical Trials

The landscape of research for Choroideremia (CHM) has moved quickly over the last decade. While we do not yet have a widely approved cure, the field is transitioning from early “first-generation” experiments to more targeted and refined approaches. It is important to approach emerging treatments with a balance of hope and realistic caution.

The Gene Therapy Journey (AAV2-REP1)

Gene therapy using a virus (AAV2) to deliver a healthy copy of the CHM gene has been the most high-profile area of research. The goal of this therapy is to provide the instructions for making the missing REP-1 protein ^[1][2].

• Early Successes: Initial small-scale trials (Phase 1/2) showed significant promise, with some patients maintaining or even gaining vision ^[3][4].
• Phase 3 Outcomes: Larger, more recent Phase 3 clinical trials (such as the STAR trial) unfortunately did not meet their “primary endpoint.” This means they failed to show a statistically significant difference in visual acuity between the treated group and the untreated group after one year ^[5].
• Lessons Learned: These results do not mean gene therapy is impossible; they suggest that visual acuity (the eye chart) may not be the best way to measure success, or that the treatment may need to be given much earlier in life to be effective ^[6][7].

Surgical Risks: The Subretinal Challenge

In most current gene therapy trials, the drug is delivered via a subretinal injection. This involves a surgeon carefully injecting the fluid underneath the retina, which temporarily lifts it up (a controlled foveal detachment) ^[3].

While surgeons are highly skilled, this procedure carries specific risks, especially for those in late-stage disease:

• Retinal Damage: The physical act of detaching the retina can sometimes damage the fragile remaining cells in the central “island” ^[3][5].
• Inflammation: The body may react to the viral vector, causing inflammation that needs to be managed with steroids.
• Progression Window: Because of these risks, researchers are debating whether the procedure is safe for those with very little remaining vision or if it should be reserved for younger patients with more robust retinas.

Alternative Research Paths

Beyond traditional gene replacement, scientists are exploring other ways to fix the underlying genetic error:

• Nonsense Suppression: For patients with a “nonsense mutation” (where the gene has a premature “stop sign”), certain drugs are being tested that help the cell “read through” the stop sign to produce the full protein ^[8].
• Antisense Oligonucleotides (ASOs): These are tiny “genetic patches” that can bind to the RNA and correct specific errors, such as splicing mistakes ^[9].
• Stem Cell Therapy: This research aims to replace the cells that have already died (RPE or photoreceptors) with new, healthy cells grown in a lab.
• Optogenetics: This approach uses gene therapy to make surviving non-visual cells in the eye sensitive to light, potentially restoring some light perception even in advanced stages.

How to Get Involved

Clinical trial enrollment is highly specific. You generally must have:

1. Molecular Confirmation: A genetic test proving you have a mutation in the CHM gene ^[2][NCT02435940].
2. Specific Vision Criteria: Many trials require you to have vision within a certain range—neither too “good” nor too “poor” [NCT06375239].
3. Active Registration: The best way to be matched with a trial is to join a registry like My Retina Tracker® (a free, secure global database run by the Foundation Fighting Blindness) [NCT02435940]. International patients should also regularly check ClinicalTrials.gov or consult with their local retinal specialist about regional registries.